Good Morning -
We are combining lists for LASA as we integrate as a System. One of the discussion points is the addition of Biosimilars to the list. For the most part we are using the naming as generic (brand) for these agents when character limits allow.
Have others added these to the LASA list or as a separate list within the policy?
Do you do all the available agents or just the ones on formulary.